Northern Trust Corp Increases Holdings in Harrow, Inc. (NASDAQ:HROW)

Northern Trust Corp grew its stake in Harrow, Inc. (NASDAQ:HROW) by 7.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 319,084 shares of the company’s stock after acquiring an additional 22,266 shares during the quarter. Northern Trust Corp owned about 0.90% of Harrow worth $10,705,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of HROW. Tower Research Capital LLC TRC raised its position in shares of Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock valued at $55,000 after buying an additional 1,462 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of Harrow during the 4th quarter worth approximately $78,000. AlphaQuest LLC lifted its stake in Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock worth $118,000 after purchasing an additional 2,889 shares in the last quarter. Federated Hermes Inc. acquired a new stake in shares of Harrow in the fourth quarter valued at $214,000. Finally, Maridea Wealth Management LLC purchased a new position in Harrow during the 4th quarter valued at about $222,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on HROW. B. Riley dropped their price target on shares of Harrow from $69.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. HC Wainwright raised their target price on shares of Harrow from $57.00 to $60.00 and gave the company a “buy” rating in a report on Monday, May 12th.

Harrow Stock Performance

Shares of HROW opened at $28.41 on Friday. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -30.22 and a beta of 0.41. Harrow, Inc. has a 52-week low of $15.97 and a 52-week high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The stock has a 50 day moving average price of $25.02 and a 200 day moving average price of $31.91.

Harrow (NASDAQ:HROW) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.40). The firm had revenue of $47.83 million for the quarter, compared to analysts’ expectations of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. Research analysts predict that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.